NCT01327924View on ClinicalTrials.gov

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenGenetic DisorderTurner SyndromeFoetal Growth ProblemSmall for Gestational AgeChronic Kidney DiseaseChronic Renal InsufficiencyDelivery Systems
Interventions
DRUG

Norditropin NordiFlex®

Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.

Trial Locations (1)

92932

Paris La Défense Cedex

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY